Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design Verification Testing for Prefilled Syringes: A Structured Best-Practice Framework.

Pharmaceutics·2026
Same author

Consideration of patient phenotypes in geographic atrophy due to age-related macular degeneration.

BMJ open ophthalmology·2025
Same author

Pegcetacoplan for Geographic Atrophy Over 30 Months: Data From OAKS, DERBY, and the GALE Long-Term Extension Study.

Ophthalmic surgery, lasers & imaging retina·2025
Same author

ACUTE MACULAR NEURORETINOPATHY FOLLOWING MODERNA mRNA COVID-19 VACCINATION.

Retinal cases & brief reports·2025
Same author

Choroidal Nevus with Mega Druse.

Ophthalmology. Retina·2025
Same author

Retinal Vessel Plexus Differentiation Based on OCT Angiography Using Deep Learning.

Ophthalmology science·2024
Same journal

Persistent placoid maculopathy: long term outcomes and prognostic factors.

Retina (Philadelphia, Pa.)·2026
Same journal

ANTI-VEGF THERAPY SWITCHING RETINAL DISEASES: Characterizing Clinical Manifestations and Common Involved Genes: ERRATUM.

Retina (Philadelphia, Pa.)·2026
Same journal

THE EFFICACY AND SAFETY OF SUBRETINAL BALANCED SALT SOLUTION INJECTION IN DIABETIC MACULAR EDEMA WITH HARD EXUDATES: ERRATUM.

Retina (Philadelphia, Pa.)·2026
Same journal

EVALUATING CLINICAL OUTCOMES OF AMNIOTIC MEMBRANE COVERAGE COMBINED WITH EARLY VITRECTOMY IN THE MANAGEMENT OF PERFORATING GLOBE INJURIES.

Retina (Philadelphia, Pa.)·2026
Same journal

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Retina (Philadelphia, Pa.)·2026
Same journal

Severe retinal non-perfusion is associated with fewer retinal lesions on ultra-wide field fundus photography in proliferative diabetic retinopathy.

Retina (Philadelphia, Pa.)·2026
See all related articles

Related Experiment Video

Updated: Dec 8, 2025

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
07:13

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

Published on: December 7, 2016

13.7K

PARTICULATE MATTER FROM SYRINGES USED FOR INTRAVITREAL INJECTIONS.

Susan M Dounce1, Olga Laskina1, Roger A Goldberg2

  • 1West Pharmaceutical Services, Inc., Exton, Pennsylvania; and.

Retina (Philadelphia, Pa.)
|September 21, 2020
PubMed
Summary
This summary is machine-generated.

Different syringes used for anti-vascular endothelial growth factor drugs impact particle load. Lubricant-free syringes minimize particles, while oleamide-lubricated ones show time-dependent increases, potentially forming visible particles in bevacizumab formulations.

More Related Videos

Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis
07:24

Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis

Published on: February 6, 2021

12.4K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.0K

Related Experiment Videos

Last Updated: Dec 8, 2025

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
07:13

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

Published on: December 7, 2016

13.7K
Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis
07:24

Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis

Published on: February 6, 2021

12.4K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.0K

Area of Science:

  • Ophthalmology
  • Materials Science
  • Pharmaceutical Science

Background:

  • Syringe preparation methods for anti-vascular endothelial growth factor (VEGF) drugs vary, impacting particle risk in retinal disease treatment.
  • Syringe selection, preparation, and storage are critical factors influencing vitreous particle injection risk.

Purpose of the Study:

  • To evaluate and compare particle loads generated by different syringe types over time.
  • To assess the impact of syringe materials and lubricants on particle formation in drug formulations.

Main Methods:

  • Four syringe types were tested: plastic (silicone oil or oleamide lubricated), glass (baked-on silicone), and lubricant-free polymer.
  • Particles were quantified using flow imaging after rinsing with water or filling with buffer over time.
  • Particle formation in a bevacizumab formulation was also characterized.

Main Results:

  • Insulin syringes exhibited very high particle counts.
  • Oleamide-lubricated syringes showed fewer initial particles but increased over time, with visible particles forming after 30 days.
  • Lubricant-free polymer syringes and baked-on silicone glass syringes demonstrated low particle levels (≥10 μm), with lubricant-free syringes showing the lowest levels (≥1 μm) and minimal particle generation with bevacizumab agitation.

Conclusions:

  • Intrinsic particle loads vary significantly between syringe types, affecting the final drug product.
  • Oleamide-lubricated transfer syringes, often used for bevacizumab, present time-dependent particle loads and risk visible particle formation.
  • Lubricant-free polymer syringes offer the lowest particle burden, crucial for intravitreal injections.